RecruitingNCT03458832
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Studying Facioscapulohumeral dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Kansas Medical Center
- Principal Investigator
- Jeffrey Statland, MDUniversity of Kansas Medical Center
- Intervention
- FSHD-specific functional rating scale(diagnostic_test)
- Enrollment
- 320 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2018 – 2027
Study locations (14)
- University of California Los Angeles, Los Angeles, California, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- University of Rochester Medical Center, Rochester, New York, United States
- The Ohio State University, Columbus, Ohio, United States
- University of Utah, Salt Lake City, Utah, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- University of Washington, Seattle, Washington, United States
- Chu De Nice, Nice, France
- Institut de Myologie, Paris, France
- Ludwig-Maximilians-Universität München, München, Germany
- Centro Clinico NeMO, Milan, Italy
- Radboud Unviersity, Nijmegen, Netherlands
- University of College London - Queens Square, London, United Kingdom
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS) · FSHD Society · Friends Research Institute, Inc. · Muscular Dystrophy Association · AFM Telethon · University of Rochester · Leiden University Medical Center · Dyne Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03458832 on ClinicalTrials.govOther trials for Facioscapulohumeral dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07086521Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)Restem, LLC.
- RECRUITINGPHASE3NCT07038200A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDAvidity Biosciences, Inc.
- RECRUITINGPHASE1, PHASE2NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyEpicrispr Biotechnologies, Inc.
- ENROLLING BY INVITATIONNCT07164937Imaging and Gait Analysis in FSHD PatientsFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06911190Ten Year Follow-up in FSHD: the FOCUS 3 StudyRadboud University Medical Center
- RECRUITINGNCT07409142BetterLife FSHD: A Patient-driven Health and Research PlatformFSHD Society
- ENROLLING BY INVITATIONPHASE2NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity Biosciences, Inc.
- RECRUITINGNANCT06600308Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular DystrophiesCentre Hospitalier Universitaire Dijon